



MEN

FIRST CANCER SITE  
**PANCREAS**PANCREAS  
POOL AIRTUM 1976-2010, MEN:

Number of subjects alive at the beginning of the interval, person-years at risk (PY), number of Observed (O) second cancers, Standardized Incidence Ratio (SIR) and Excess Absolute Risk (EAR) x 1000 cancer patients by second cancer site and follow-up period.

PANCREAS  
POOL AIRTUM 1976-2010, UOMINI:

Numero di soggetti vivi all'inizio dell'intervallo, anni persona a rischio (PY), numero di secondi tumori osservati (O), rapporto standardizzato di incidenza (SIR) ed eccesso assoluto di rischio (EAR) x 1000 pazienti per sede di secondo tumore e periodo di follow-up.

months after first cancer ▶	≥2 months		≥0 months		0-1 months		2-11 months		12-59 months		60-119 months		≥120 months		≥2 months	≥0 months		
	No. of subjects alive at interval beginning ▶	Person-years ▶	O	SIR	O	SIR	O	SIR	O	SIR	O	SIR	O	SIR	EAR	EAR		
<b>SECOND CANCER SITE</b>			<b>O</b>	<b>SIR</b>	<b>O</b>	<b>SIR</b>	<b>O</b>	<b>SIR</b>	<b>O</b>	<b>SIR</b>	<b>O</b>	<b>SIR</b>	<b>O</b>	<b>SIR</b>	<b>EAR</b>	<b>EAR</b>		
<b>ALL SITES, BUT SKIN AND PANCREAS</b>	187	13693	187	<b>0.70</b>	436	<b>1.31</b>	249	<b>3.92</b>	63	<b>0.49</b>	89	0.91	21	0.68	14	1.13	<b>-5.97</b>	<b>6.18</b>
HEAD AND NECK	15		15	1.32	19	1.35	4	1.48	4	0.71	7	1.68	3	2.54	1	2.30	0.26	0.29
ORAL CAVITY	4		4	1.50	4	1.21	0	0.00	0	0.00	1	1.02	2	7.15	1	9.45	0.10	0.04
PHARYNX	3		3	1.24	5	1.68	2	3.56	0	0.00	2	2.24	1	4.06	0	0.00	0.04	0.12
LARYNX	8		8	1.27	10	1.28	2	1.32	4	1.29	4	1.74	0	0.00	0	0.00	0.12	0.13
OESOPHAGUS	3		3	1.02	7	1.93	4	<b>5.68</b>	1	0.71	1	0.94	1	3.15	0	0.00	0.01	0.20
STOMACH	16		16	0.96	38	<b>1.82</b>	22	<b>5.26</b>	5	0.62	10	1.66	1	0.53	0	0.00	-0.05	<b>1.02</b>
COLON RECTUM	20		20	<b>0.53</b>	64	<b>1.38</b>	44	<b>4.98</b>	4	<b>0.23</b>	15	1.09	1	0.23	0	0.00	<b>-1.28</b>	1.05
COLON	14		14	<b>0.54</b>	43	1.36	29	<b>4.82</b>	4	<b>0.33</b>	9	0.96	1	0.33	0	0.00	-0.86	0.67
RECTUM	6		6	0.51	21	1.43	15	<b>5.34</b>	0	<b>0.00</b>	6	1.38	0	0.00	0	0.00	-0.43	0.38
LIVER	3		3	<b>0.27</b>	11	0.80	8	<b>3.05</b>	1	0.19	2	0.49	0	0.00	0	0.00	<b>-0.59</b>	-0.17
GALLBLADDER	3		3	1.01	7	1.91	4	<b>5.59</b>	1	0.72	1	0.93	0	0.00	1	7.00	0.00	0.20
PANCREAS	0		0	<b>0.00</b>	0	<b>0.00</b>	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	<b>-0.54</b>	<b>-0.55</b>
LUNG	35		35	0.73	87	<b>1.46</b>	52	<b>4.47</b>	9	<b>0.39</b>	12	0.69	10	1.86	4	1.94	-0.96	<b>1.62</b>
SKIN MELANOMA	2		2	0.53	4	0.86	2	2.41	2	1.14	0	0.00	0	0.00	0	0.00	-0.13	-0.04
MESOTHELIOMA	1		1	0.70	1	0.57	0	0.00	0	0.00	1	1.89	0	0.00	0	0.00	-0.03	-0.05
KAPOSI SARCOMA	1		1	1.70	1	1.37	0	0.00	1	3.54	0	0.00	0	0.00	0	0.00	0.03	0.02
SOFT TISSUE	0		0	0.00	1	0.86	1	4.58	0	0.00	0	0.00	0	0.00	0	0.00	-0.07	-0.01
BONE	0		0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.02	-0.02
BREAST	1		1	1.71	1	1.38	0	0.00	1	3.60	0	0.00	0	0.00	0	0.00	0.03	0.02
PROSTATE	37		37	<b>0.68</b>	65	0.98	28	<b>2.27</b>	17	0.68	15	0.75	3	0.46	2	0.75	-1.26	-0.09
TESTIS	0		0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.02	-0.02
KIDNEY AND RENAL PELVIS	8		8	0.95	32	<b>3.08</b>	24	<b>12.38</b>	1	0.25	7	2.25	0	0.00	0	0.00	-0.03	<b>1.29</b>
BLADDER AND URINARY TRACT	21		21	0.69	47	1.24	26	<b>3.56</b>	6	<b>0.41</b>	9	0.81	1	0.29	5	<b>3.56</b>	-0.70	0.54
URINARY BLADDER	19		19	0.65	41	1.13	22	<b>3.15</b>	5	<b>0.36</b>	8	0.75	1	0.30	5	<b>3.73</b>	-0.75	0.28
URINARY TRACT	2		2	1.54	6	<b>3.71</b>	4	<b>12.64</b>	1	1.63	1	2.13	0	0.00	0	0.00	0.05	0.26
BRAIN AND CENTRAL NERVOUS SYSTEM	1		1	0.32	2	0.52	1	1.38	0	0.00	1	0.87	0	0.00	0	0.00	-0.16	-0.11
THYROID	1		1	0.80	1	0.66	0	0.00	0	0.00	0	0.00	1	7.28	0	0.00	-0.02	-0.03
HODGKIN LYMPHOMA	0		0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.04	-0.04
NON-HODGKIN LYMPHOMA	6		6	0.78	16	1.69	10	<b>5.60</b>	5	1.37	1	0.35	0	0.00	0	0.00	-0.12	0.39
MYELOMA	0		0	0.00	2	0.45	2	2.31	0	0.00	0	0.00	0	0.00	0	0.00	-0.26	-0.15
LEUKAEMIAS	5		5	0.80	11	1.41	6	<b>3.94</b>	2	0.67	3	1.31	0	0.00	0	0.00	-0.09	0.19
LYMPHOID LEUKAEMIAS	4		4	1.32	8	2.13	4	<b>5.46</b>	2	1.38	2	1.82	0	0.00	0	0.00	0.07	0.25
MYELOID LEUKAEMIAS	1		1	0.36	3	0.86	2	2.96	0	0.00	1	0.97	0	0.00	0	0.00	-0.13	-0.03
OTHER LEUKAEMIAS	0		0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.03	-0.03
OTHER AND ILL DEFINED SITES	8		8	0.56	19	1.08	11	<b>3.21</b>	3	0.45	4	0.78	0	0.00	1	1.44	<b>-0.45</b>	0.08

Decrease/Difetto  
Increase/Eccesso

Observed cases  
Casi osservati

SIR Standardized Incidence Ratio  
Rapporto standardizzato di incidenza

EAR Excess Absolute Risk  
Eccesso assoluto di rischio



WOMEN

FIRST CANCER SITE  
**PANCREAS**PANCREAS  
POOL AIRTUM 1976-2010, WOMEN:

Number of subjects alive at the beginning of the interval, person-years at risk (PY), number of Observed (O) second cancers, Standardized Incidence Ratio (SIR) and Excess Absolute Risk (EAR) x 1000 cancer patients by second cancer site and follow-up period.

PANCREAS  
POOL AIRTUM 1976-2010, DONNE:

Numero di soggetti vivi all'inizio dell'intervallo, anni persona a rischio (PY), numero di secondi tumori osservati (O), rapporto standardizzato di incidenza (SIR) ed eccesso assoluto di rischio (EAR) x 1000 pazienti per sede di secondo tumore e periodo di follow-up.

months after first cancer ▶	≥2 months		≥0 months		0-1 months		2-11 months		12-59 months		60-119 months		≥120 months		≥2 months	≥0 months
	No. of subjects alive at interval beginning ▶	15686	23500		23500		15686		4234		548		154		15686	23500
Person-years ▶	14542	17797		3255		6821		5524		1609		589		14542	17797	
SECOND CANCER SITE	O	SIR	O	SIR	O	SIR	O	SIR	O	SIR	O	SIR	O	SIR	EAR	EAR
ALL SITES, BUT SKIN AND PANCREAS	129	0.78	343	1.66	214	5.31	51	0.64	54	0.88	17	0.94	7	1.00	-2.57	7.66
HEAD AND NECK	2	0.92	3	1.11	1	1.94	1	0.96	1	1.23	0	0.00	0	0.00	-0.01	0.02
ORAL CAVITY	2	1.66	2	1.34	0	0.00	1	1.76	1	2.24	0	0.00	0	0.00	0.05	0.03
PHARYNX	0	0.00	1	1.79	1	9.62	0	0.00	0	0.00	0	0.00	0	0.00	-0.03	0.02
LARYNX	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.04	-0.04
OESOPHAGUS	1	1.13	1	0.90	0	0.00	1	2.34	0	0.00	0	0.00	0	0.00	0.01	-0.01
STOMACH	5	0.46	21	1.52	16	5.46	1	0.19	2	0.51	0	0.00	2	4.32	-0.40	0.41
COLON RECTUM	20	0.73	58	1.68	38	5.52	5	0.38	10	0.99	4	1.33	1	0.84	-0.52	1.32
COLON	15	0.76	47	1.89	32	6.45	4	0.42	6	0.82	4	1.83	1	1.15	-0.33	1.25
RECTUM	5	0.65	11	1.14	6	3.12	1	0.27	4	1.42	0	0.00	0	0.00	-0.18	0.08
LIVER	2	0.41	7	1.14	5	4.02	0	0.00	2	1.11	0	0.00	0	0.00	-0.20	0.05
GALLBLADDER	3	0.76	19	3.82	16	15.50	1	0.52	2	1.40	0	0.00	0	0.00	-0.06	0.79
PANCREAS	0	0.00	1	0.11	1	0.54	0	0.00	0	0.00	0	0.00	0	0.00	-0.50	-0.46
LUNG	12	1.09	27	1.98	15	5.72	4	0.77	5	1.23	2	1.65	1	2.10	0.07	0.75
SKIN MELANOMA	3	1.01	3	0.83	0	0.00	0	0.00	2	1.78	0	0.00	1	7.66	0.00	-0.04
MESOTHELIOMA	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.03	-0.03
KAPOSI SARCOMA	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.02	-0.02
SOFT TISSUE	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.05	-0.05
BONE	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.01	-0.01
BREAST	31	0.74	75	1.47	44	4.62	14	0.71	11	0.70	5	1.11	1	0.59	-0.73	1.34
CERVIX UTERI	0	0.00	1	0.38	1	1.97	0	0.00	0	0.00	0	0.00	0	0.00	-0.15	-0.09
CORPUS UTERI	7	0.92	10	1.07	3	1.73	2	0.55	4	1.40	1	1.26	0	0.00	-0.04	0.04
OVARY	7	1.33	19	2.91	12	9.59	6	2.37	1	0.51	0	0.00	0	0.00	0.12	0.70
KIDNEY AND RENAL PELVIS	3	0.73	25	4.90	22	22.56	3	1.53	0	0.00	0	0.00	0	0.00	-0.08	1.12
BLADDER AND URINARY TRACT	6	0.88	18	2.12	12	7.07	1	0.31	2	0.80	3	4.02	0	0.00	-0.05	0.53
URINARY BLADDER	5	0.79	16	2.03	11	6.99	1	0.33	1	0.43	3	4.33	0	0.00	-0.09	0.46
URINARY TRACT	1	2.05	2	3.26	1	8.02	0	0.00	1	5.57	0	0.00	0	0.00	0.04	0.08
BRAIN AND CENTRAL NERVOUS SYSTEM	1	0.41	3	0.98	2	3.45	1	0.85	0	0.00	0	0.00	0	0.00	-0.10	0.00
THYROID	4	1.46	6	1.82	2	3.69	1	0.81	3	2.79	0	0.00	0	0.00	0.09	0.15
HODGKIN LYMPHOMA	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.03	-0.03
NON-HODGKIN LYMPHOMA	4	0.62	9	1.13	5	3.25	3	0.97	1	0.42	0	0.00	0	0.00	-0.17	0.06
MYELOMA	3	0.97	8	2.08	5	6.51	1	0.67	1	0.88	1	3.03	0	0.00	-0.01	0.23
LEUKAEMIAS	3	0.68	10	1.81	7	6.22	1	0.47	2	1.24	0	0.00	0	0.00	-0.10	0.25
LYMPHOID LEUKAEMIAS	2	1.02	8	3.25	6	11.86	1	1.04	1	1.40	0	0.00	0	0.00	0.00	0.31
MYELOID LEUKAEMIAS	1	0.49	2	0.78	1	1.94	0	0.00	1	1.33	0	0.00	0	0.00	-0.07	-0.03
OTHER LEUKAEMIAS	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.03	-0.03
OTHER AND ILL DEFINED SITES	12	0.90	20	1.19	8	2.31	5	0.78	5	1.03	1	0.66	1	1.66	-0.09	0.18

Decrease/Difetto  
Increase/Eccesso

Observed cases  
Casi osservati

SIR Standardized Incidence Ratio  
Rapporto standardizzato di incidenza

EAR Excess Absolute Risk  
Eccesso assoluto di rischio